BioCentury | Mar 30, 2009

Ebb & Flow

With Genentech 's takeout now complete, industry watchers will be looking for when the biotech's executives will head for the exits. Based on the structure of the bonus payouts in the employee retention plan, a...
BC Extra | Apr 4, 2008
Top Story

sanofi-aventis drops two Genfit compounds

sanofi-aventis (Euronext:SAN; NYSE:SNY) discontinued development of AVE8134 and AVE0847, which were developed with Genfit (Euronext:ALGFT) under a 1999 collaboration. AVE8134 is a peroxisome proliferation activated receptor (PPAR) alpha agonist, and AVE0847 is a PPAR alpha...
BioCentury | Dec 10, 2007
Product Development

PPAR vigilance

PPAR vigilance PPAR vigilance Cardiovascular endpoints for selected compounds targeting the peroxisome proliferation activated receptor (PPAR) for diabetes, as described by the companies to BioCentury. At least four Phase II or Phase III studies are...
BioCentury | May 28, 2007
Politics, Policy & Law

Next up

Next up Company Product Description Status GlaxoSmithKline Avandia rosiglitazone PPAR gamma agonist Mkt Eli Lilly/Takeda Actos pioglitazone PPAR gamma agonist Mkt Metabolex/J&J MBX-102 Selective PPAR gamma modulator Ph II/III Perlegen/Mitsubishi Netoglitazone (PGX-510) PPAR gamma agonist...
Items per page:
1 - 4 of 4